Drawing for VLEXITURN

USPTO serial 77340033

VLEXITURN

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
TRUSILO, KELLY JEAN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VLEXITURN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccinesACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 23, 2012MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 23, 2012ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 16, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2011EX5GSOU EXTENSION 5 GRANTED
Sep 13, 2011EXT5SOU EXTENSION 5 FILED
Sep 13, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 26, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2011EX4GSOU EXTENSION 4 GRANTED
Mar 23, 2011EXT4SOU EXTENSION 4 FILED
Mar 23, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 18, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 17, 2010EX3GSOU EXTENSION 3 GRANTED
Sep 15, 2010EXT3SOU EXTENSION 3 FILED
Sep 15, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 10, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 9, 2010EX2GSOU EXTENSION 2 GRANTED
Apr 9, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 15, 2010EXT2SOU EXTENSION 2 FILED
Mar 15, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 9, 2009EX1GSOU EXTENSION 1 GRANTED
Sep 9, 2009EXT1SOU EXTENSION 1 FILED
Sep 9, 2009EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 27, 2009TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 27, 2009TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 24, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 11, 2009TMBNTTAB RELEASE CASE TO TRADEMARKS
Feb 11, 2009OP.TOPPOSITION TERMINATED NO. 999999
Feb 11, 2009OP.DOPPOSITION DISMISSED NO. 999999
Aug 29, 2008OP.IOPPOSITION INSTITUTED NO. 999999
Mar 19, 2008ETOFEXTENSION OF TIME TO OPPOSE RECEIVED
Mar 4, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 13, 2008NPUBNOTICE OF PUBLICATION
Jan 27, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 27, 2008ALIEASSIGNED TO LIE
Dec 14, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Dec 8, 2007DOCKASSIGNED TO EXAMINER
Dec 5, 2007MPMKNOTICE OF PSEUDO MARK MAILED
Dec 4, 2007NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance